Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 3/20 | 0.42 |
| ▸ | HTR1B | P28222 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 5/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323781 | 0.83 | HTR1A (0.43) | HTR1DHTR1BHTR1ASLC6A4DRD4 | |
| SCHEMBL6528187 | 0.81 | HTR1D (0.43) | HTR1DHTR1BHTR1ASLC6A4 | |
| SCHEMBL1322969 | 0.79 | HTR1A (0.57) | HTR1DHTR1BHTR1A | |
| SCHEMBL13633559 | 0.79 | ADRA2A (0.48) | HTR1ASLC6A4 | |
| SCHEMBL1322961 | 0.78 | HTR1D (0.55) | HTR1DHTR1BHTR1ASLC6A4HTR2A | |
| SCHEMBL1406124 | 0.77 | HTR1D (0.39) | HTR1DHTR1BHTR1ASLC6A4DRD4 | |
| SCHEMBL1322976 | 0.77 | HTR1A (0.51) | HTR1DHTR1BHTR1ASLC6A4DRD4 | |
| SCHEMBL6820019 | 0.76 | HTR1A (0.63) | HTR1A | |
| SCHEMBL1322782 | 0.76 | DRD2 (0.50) | HTR1ADRD4HTR2A | |
| SCHEMBL1324162 | 0.76 | HTR7 (0.51) | HTR1DHTR1BHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058277-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2011-11-15 | — | — | US | claimed |
| EP-1497279-B1 | SUBSTITUTED INDOLES AND THEIR USE AS 5HT-REUPTAKE INHIBITORS AND AS 5HT LIGANDS | MERCK PATENT GMBH (DE) | 2011-03-09 | — | — | EP | claimed |
| US-20090291963-A1 | SUBSTITUTED INDOLES | SCHADT OLIVER | 2009-11-26 | — | — | US | claimed |
| US-7572796-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2009-08-11 | — | — | US | claimed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | claimed |
| US-20050153980-A1 | Substituted indoles | MERCK PATENT GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| US-8058277-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-8058277-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-8058277-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| EP-1497279-B1 | SUBSTITUTED INDOLES AND THEIR USE AS 5HT-REUPTAKE INHIBITORS AND AS 5HT LIGANDS | MERCK PATENT GMBH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20090291963-A1 | SUBSTITUTED INDOLES | SCHADT OLIVER | 2009-11-26 | — | — | US | disclosed |
| US-20090291963-A1 | SUBSTITUTED INDOLES | SCHADT OLIVER | 2009-11-26 | — | — | US | disclosed |
| US-20090291963-A1 | SUBSTITUTED INDOLES | SCHADT OLIVER | 2009-11-26 | — | — | US | disclosed |
| US-7572796-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7572796-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7572796-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
| US-20050153980-A1 | Substituted indoles | MERCK PATENT GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054459-A1 | Substituted indoles | TPH2, TPH1, HTR1A | HTR1D 13/4885HTR1B 14/4885HTR1A 3/4885 |
| US-20090291963-A1 | SUBSTITUTED INDOLES | TPH2, TPH1, HTR1A | HTR1D 11/4885HTR1B 12/4885HTR1A 3/4885 |
| US-20050153980-A1 | Substituted indoles | TPH2, TPH1, HTR1A | HTR1D 11/4885HTR1B 12/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.